Annovis Bio (NYSE:ANVS) Issues Earnings Results, Misses Expectations By $0.19 EPS

Annovis Bio (NYSE:ANVS) issued its quarterly earnings results on Wednesday. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.15) by ($0.19), Fidelity Earnings reports.

Shares of NYSE:ANVS opened at $5.80 on Friday. Annovis Bio has a 1 year low of $2.42 and a 1 year high of $10.61. The business’s 50 day moving average is $5.36.

Separately, Maxim Group assumed coverage on Annovis Bio in a research report on Thursday, June 18th. They set a “buy” rating and a $12.00 price target on the stock.

Annovis Bio Company Profile

Annovis Bio, Inc, a clinical stage drug platform company, focuses on developing compounds to address neurodegeneration. The company's lead compound is ANVS-401, which is in Phase 2a clinical trials for the treatment of chronic neurodegenerative diseases, such as Down syndrome, Alzheimer's disease (AD), and Parkinson's disease.

Read More: What is a Leveraged Buyout (LBO)?

Receive News & Ratings for Annovis Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Annovis Bio and related companies with MarketBeat.com's FREE daily email newsletter.